Biomedical Engineering Reference
In-Depth Information
15. Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little
M. (1999) A bispecific diabody that mediates natural killer cell
cytotoxicity against xenotransplantated human Hodgkin's
tumors. Blood 94(8), 2562-2568.
16. Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J,
Benner A, Moldenhauer G, et al. (2000) Cure of Burkitt's
lymphoma in severe combined immunodeficiency mice by T
cells, tetravalent CD3
CD19 tandem diabody, and CD28
costimulation. Cancer Res. 60(16), 4336-4341.
17. Ridgway JB, Presta LG, Carter P. (1996) “Knobs-into-holes”
engineering of antibody CH3 domains for heavy chain hetero-
dimerization. Protein Eng. 9(7), 617-621.
18. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C,
Woodward A, et al. (2010) Enhancing antibody Fc heterodimer
formation through electrostatic steering effects: applications
to bispecific molecules and monovalent IgG. J. Biol. Chem.
285(25), 19637-19646.
19. Muda M, Gross AW, Dawson JP, He C, Kurosawa E,
Schweickhardt R, et al. (2011) Therapeutic assessment of
SEED: a new engineered antibody platform designed to gen-
erate mono- and bispecific antibodies. Protein Eng. Des. Sel.
24(5), 447-454.
20. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R,
Durr H, et al. (2011) Immunoglobulin domain crossover as a
generic approach for the production of bispecific IgG anti-
bodies. Proc. Natl. Acad. Sci. USA 108(27), 11187-11192.
21. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A,
et al. (2007) Simultaneous targeting of multiple disease medi-
ators by a dual-variable-domain immunoglobulin. Nat.
Biotechnol. 25(11), 1290-1297.
22. Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, et al.
(2010) Chemical generation of bispecific antibodies. Proc.
Natl. Acad. Sci. USA 107(52), 22611-22616.
23. Veri M-C, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N,
et al. (2010) Therapeutic control of B cell activation via
recruitment of Fcgamma receptor IIb (CD32B) inhibitory
function with a novel bispecific antibody scaffold. Arthritis
Rheum. 62(7), 1933-1943.
24. Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, et al.
(2010) Effector cell recruitment with novel Fv-based dual-
affinity re-targeting protein leads to potent tumor cytolysis and
in vivo B-cell depletion. J. Mol. Biol. 399(3), 436-449.
25. Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, et al.
(2011) Application of dual affinity retargeting molecules to
achieve optimal redirected T-cell killing of B-cell lymphoma.
Blood 117(17), 4542-4551.
26. Litowski JR, Hodges RS. (2002) Designing heterodimeric two-
stranded alpha-helical coiled-coils. Effects of hydrophobicity
and alpha-helical propensity on protein folding, stability, and
specificity. J. Biol. Chem. 277(40), 37272-37279.
27. Hakoda M, Kamatani N, Hayashimoto-Kurumada S, Silverman
GJ, Yamanaka H, Terai C, et al. (1996) Differential binding
avidities of human IgMfor staphylococcal proteinAderive from
specific germ-line VH3 gene usage. J. Immunol. 157(7),
2976-2981.
28. Curnow RT. (1997) Clinical experience with CD64-directed
immunotherapy. An overview Cancer Immunol. Immunother.
45(3-4), 210-215.
29. Muller D, Kontermann RE. (2007) Recombinant bispecific
antibodies for cellular cancer immunotherapy. Curr. Opin.
Mol. Ther. 9(4), 319-326.
30. Muller D, Kontermann RE. (2010) Bispecific antibodies for
cancer immunotherapy: Current perspectives. BioDrugs 24(2),
89-98.
31. Baeuerle PA, Reinhardt C. (2009) Bispecific T-cell engaging
antibodies for cancer therapy. Cancer Res. 69(12), 4941-4944.
32. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop
S, et al. (2008) Tumor regression in cancer patients by very
low doses of a T cell-engaging antibody. Science 321(5891),
974-977.
Search WWH ::
Custom Search